{
    "id": 50745,
    "name": "diffuse large B-cell lymphoma",
    "source": "DOID",
    "definition": "A B-cell lymphoma that is a cancer of B cells presenting as an aggressive tumour which can arise in virtually any part of the body. [url:http\\://en.wikipedia.org/wiki/Diffuse_large_B-cell_lymphoma, url:https\\://www.ncbi.nlm.nih.gov/pubmed/28487884]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0050745",
    "evidence": [
        {
            "id": 1115,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, STS2825 demonstrated effective inhibition of MYD88 homodimerization and signalling in cultured cells and is currently being evaluated in preclinical studies of B cell lymphoma (Blood Lymph Canc 2013; 3: 53-61).",
            "molecularProfile": {
                "id": 593,
                "profileName": "MYD88 wild-type"
            },
            "therapy": {
                "id": 1563,
                "therapyName": "ST2825",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 861,
                    "pubMedId": null,
                    "title": "Emerging targets in human lymphoma: targeting the MYD88 mutation",
                    "url": null
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1426,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, UNC1999 treatment reduced H3K27me3 levels, decreased proliferation, and increased cell death in diffuse large B-cell lymphoma cells harboring an EZH2 Y641N mutation in cell culture (PMID: 23614352).",
            "molecularProfile": {
                "id": 672,
                "profileName": "EZH2 Y641N"
            },
            "therapy": {
                "id": 1757,
                "therapyName": "UNC1999",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1266,
                    "pubMedId": 23614352,
                    "title": "An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23614352"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1809,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAE684 demonstrated efficacy by repressing Alk signaling, inducing apoptosis in cultured cells, and promoting tumor regression in cell line xenograft models of diffuse large B-cell lymphoma expressing CLTC-ALK fusions (PMID: 21494621).",
            "molecularProfile": {
                "id": 3533,
                "profileName": "CLTC - ALK"
            },
            "therapy": {
                "id": 2386,
                "therapyName": "TAE684",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2190,
                    "pubMedId": 21494621,
                    "title": "Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21494621"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2001,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Birabresib (OTX015) resulted in apoptotic activity and inhibition of Myc and downstream signaling pathways in diffuse large B-cell lymphoma cell lines in culture, and reduced tumor growth in xenograft models (PMID: 25623213).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2034,
                "therapyName": "Birabresib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2444,
                    "pubMedId": 25623213,
                    "title": "The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25623213"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2393,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rapamune (sirolimus), in combination with UCN-01 (sc-3510), resulted in apoptosis and cell cycle arrest in diffuse large B-cell lymphoma cells in culture (PMID: 19223503).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2813,
                "therapyName": "Sirolimus + UCN-01",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3021,
                    "pubMedId": 19223503,
                    "title": "Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19223503"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4283,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ISIS-STAT3rx (AZD9150) treatment resulted in tumor shrinkage in 50% (3/6) and partial response in 22% (2/6) of diffuse large B-cell lymphoma patients (PMID: 26582900).",
            "molecularProfile": {
                "id": 17606,
                "profileName": "STAT3 wild-type"
            },
            "therapy": {
                "id": 2782,
                "therapyName": "AZD9150",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4478,
                    "pubMedId": 26582900,
                    "title": "AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26582900"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4595,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, IT-901 inhibited growth of diffuse large B-cell lymphoma cells in culture (PMID: 26744524).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3551,
                "therapyName": "IT-901",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4622,
                    "pubMedId": 26744524,
                    "title": "Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-\u03baB-Controlled Oxidative Stress Responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744524"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4908,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SEL24-B489 treatment induced apoptosis in diffuse large B-cell lymphoma cells in both culture and xenograft models (Blood 126 (23):706.December 2015).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3693,
                "therapyName": "SEL24-B489",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4788,
                    "pubMedId": null,
                    "title": "A Novel Pan-PIM Kinase Inhibitor, SEL24-B489, Induces Apoptosis and Inhibits Proliferation of Diffuse Large B-Cell Lymphoma Cells through Inhibition of Protein Translation and Attenuation of Myc and NFkB Activity",
                    "url": "https://ash.confex.com/ash/2015/webprogram/Paper84427.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4909,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SEL24-B489 demonstrated a synergistic effect when combined with Ibruvica (ibrutinib) in diffuse large B-cell lymphoma cells in culture, resulting in cell growth inhibition ((Blood 126 (23):706.December 2015).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3694,
                "therapyName": "Ibrutinib + SEL24-B489",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4788,
                    "pubMedId": null,
                    "title": "A Novel Pan-PIM Kinase Inhibitor, SEL24-B489, Induces Apoptosis and Inhibits Proliferation of Diffuse Large B-Cell Lymphoma Cells through Inhibition of Protein Translation and Attenuation of Myc and NFkB Activity",
                    "url": "https://ash.confex.com/ash/2015/webprogram/Paper84427.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5128,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Aliqopa (copanlisib) treatment resulted in complete response in 6% (1/17), partial response in 6% (1/17) and stable disease in 41% (7/17) of patients with diffuse large B-cell lymphoma (PMID: 24852792).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 995,
                "therapyName": "Copanlisib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4879,
                    "pubMedId": 24852792,
                    "title": "Preliminary results of a phase II study of single agent Bay 80-6946, a Novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24852792"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5142,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Parsaclisib (INCB050465) inhibited proliferation of diffuse large B-cell lymphoma cell lines in culture and suppressed tumor growth in xenograft models (Cancer Res August 1, 2015 75; 2671).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3088,
                "therapyName": "Parsaclisib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4886,
                    "pubMedId": null,
                    "title": "INCB050465, a novel PI3K-delta inhibitor, synergizes with PIM protein kinase inhibition to cause tumor regression in a model of DLBCL",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/2671.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16519,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Parsaclisib (INCB050465) treatment demonstrated tolerability and preliminary activity in patients with refractory B-cell malignancies, and resulted in an overall response rate of 30% (7/23), complete response/complete metabolic response rate of 17% (4/23), and median duration of response of 13.5 months in patients with diffuse large B-cell lymphoma (PMID: 30803990; NCT02018861).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3088,
                "therapyName": "Parsaclisib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14606,
                    "pubMedId": 30803990,
                    "title": "Parsaclisib, a potent and highly selective PI3K\u03b4 inhibitor, in patients with relapsed or refractory B-cell malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30803990"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5143,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Parsaclisib (INCB050465) and INCB039110 combination treatment inhibited proliferation of diffuse large B-cell lymphoma cell lines in culture and induced tumor regression in xenograft models (Cancer Res August 1, 2015 75; 2671).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3097,
                "therapyName": "Itacitinib + Parsaclisib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4886,
                    "pubMedId": null,
                    "title": "INCB050465, a novel PI3K-delta inhibitor, synergizes with PIM protein kinase inhibition to cause tumor regression in a model of DLBCL",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/2671.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5173,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, high-dose TGR-1202 in combination with Ublituximab resulted in complete response in 50% (2/4) and partial response in 25% (1/4) of patients with diffuse large B-cell lymphoma (J Clin Oncol 33, 2015 (suppl; abstr 8548)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2319,
                "therapyName": "Ublituximab + Umbralisib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4899,
                    "pubMedId": null,
                    "title": "Ublituximab plus TGR-1202 activity and safety profile in relapsed/refractory B-cell NHL and high-risk CLL.",
                    "url": "http://meetinglibrary.asco.org/content/152562-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5197,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MLN0905 combined with MabThera (rituximab) resulted in a synergistic effect when treating a diffuse large B-cell lymphoma xenograft model, demonstrating a decrease in tumor volume and increased survival (PMID: 22609854).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3778,
                "therapyName": "MLN0905 + Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4909,
                    "pubMedId": 22609854,
                    "title": "MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22609854"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5198,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MLN0905 treatment resulted in decreased tumor volume in a diffuse large B-cell lymphoma xenograft model (PMID: 22609854).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3777,
                "therapyName": "MLN0905",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4909,
                    "pubMedId": 22609854,
                    "title": "MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22609854"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5236,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, diffuse large B-cell lymphoma cell lines over expressing STAT3 M206K were resistant to Inrebic (fedratinib) induced Stat3 dephosphorylation and growth inhibition in culture (PMID: 23861822).",
            "molecularProfile": {
                "id": 20332,
                "profileName": "STAT3 M206K"
            },
            "therapy": {
                "id": 911,
                "therapyName": "Fedratinib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4942,
                    "pubMedId": 23861822,
                    "title": "A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23861822"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5242,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Cerdulatinib (PRT062070) resulted in decreased viability and increased apoptosis of diffuse large B-cell lymphoma cells in culture (PMID: 25253883).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2531,
                "therapyName": "Cerdulatinib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2450,
                    "pubMedId": 25253883,
                    "title": "The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25253883"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5244,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, fostamatinib demonstrated safety, but limited efficacy in patients with diffuse large B-cell lymphoma, with an objective response rate of 3% (2/68) and stable disease in 10% (7/68) of patients (PMID: 26707592).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1528,
                "therapyName": "Fostamatinib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4952,
                    "pubMedId": 26707592,
                    "title": "A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26707592"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5999,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ST7612AA1 inhibited proliferation of diffuse large B-cell lymphoma cell lines in culture (PMID: 25671299).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3989,
                "therapyName": "ST7612AA1",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5200,
                    "pubMedId": 25671299,
                    "title": "Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25671299"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6009,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, eFT508 demonstrated anti-tumor activity in two diffuse large B-cell lymphoma cell line xenograft models, both harboring MYD88 activating mutations (Blood Dec 2015, 126 (23) 1554).",
            "molecularProfile": {
                "id": 22222,
                "profileName": "MYD88 act mut"
            },
            "therapy": {
                "id": 4005,
                "therapyName": "Tomivosertib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5231,
                    "pubMedId": null,
                    "title": "eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)",
                    "url": "http://www.bloodjournal.org/content/126/23/1554"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6010,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, eFT508 inhibited proliferation of diffuse large B-cell lymphoma cell lines in culture (Blood Dec 2015, 126 (23) 1554).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4005,
                "therapyName": "Tomivosertib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5231,
                    "pubMedId": null,
                    "title": "eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)",
                    "url": "http://www.bloodjournal.org/content/126/23/1554"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6039,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, CUDC-907 was well-tolerated, demonstrated safety, and resulted in a 56% (5/9) objective response rate, including two complete responses and three partial responses, in patients with diffuse large B-cell lymphoma (PMID: 27049457).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 709,
                "therapyName": "CUDC-907",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5256,
                    "pubMedId": 27049457,
                    "title": "Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27049457"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6344,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "In multiple clinical studies, MYD88 L265P was associated with a worse overall survival in patients with diffuse large B-cell lymphoma when compared to MYD88 wild-type (PMID: 24903481, PMID: 25055137, PMID: 26792260).",
            "molecularProfile": {
                "id": 6507,
                "profileName": "MYD88 L265P"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5531,
                    "pubMedId": 24903481,
                    "title": "MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24903481"
                },
                {
                    "id": 5532,
                    "pubMedId": 25055137,
                    "title": "High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25055137"
                },
                {
                    "id": 5533,
                    "pubMedId": 26792260,
                    "title": "MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26792260"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6551,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DLBCL cells harboring EZH2 Y641N demonstrated sensitivity to ACY-957 in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023).",
            "molecularProfile": {
                "id": 672,
                "profileName": "EZH2 Y641N"
            },
            "therapy": {
                "id": 4144,
                "therapyName": "ACY-957",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6552,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DLBCL cells harboring EZH2 Y641S demonstrated sensitivity to ACY-957 in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023).",
            "molecularProfile": {
                "id": 673,
                "profileName": "EZH2 Y641S"
            },
            "therapy": {
                "id": 4144,
                "therapyName": "ACY-957",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6554,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DLBCL cells harboring EZH2 Y641N demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023).",
            "molecularProfile": {
                "id": 672,
                "profileName": "EZH2 Y641N"
            },
            "therapy": {
                "id": 1077,
                "therapyName": "Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6557,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DLBCL cells harboring EZH2 Y641S demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023).",
            "molecularProfile": {
                "id": 673,
                "profileName": "EZH2 Y641S"
            },
            "therapy": {
                "id": 1077,
                "therapyName": "Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6558,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK126 enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641N in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023).",
            "molecularProfile": {
                "id": 672,
                "profileName": "EZH2 Y641N"
            },
            "therapy": {
                "id": 4148,
                "therapyName": "ACY-957 + GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6559,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK126 enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641S in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023).",
            "molecularProfile": {
                "id": 673,
                "profileName": "EZH2 Y641S"
            },
            "therapy": {
                "id": 4148,
                "therapyName": "ACY-957 + GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6560,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DZNeP enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641N in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023).",
            "molecularProfile": {
                "id": 672,
                "profileName": "EZH2 Y641N"
            },
            "therapy": {
                "id": 4147,
                "therapyName": "ACY-957 + DZNeP",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6561,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DZNeP enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641S in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023).",
            "molecularProfile": {
                "id": 673,
                "profileName": "EZH2 Y641S"
            },
            "therapy": {
                "id": 4147,
                "therapyName": "ACY-957 + DZNeP",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6562,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GSK126 did not alter cell-cycle progression or decrease survival in a diffuse large B-cell lymphoma cell line harboring EZH2 Y641S in culture (PMID: 25605023).",
            "molecularProfile": {
                "id": 673,
                "profileName": "EZH2 Y641S"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6563,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK126 alone did not alter cell-cycle progression in survival in a diffuse large B-cell lymphoma cell line harboring EZH2 Y641N in culture (PMID: 25605023).",
            "molecularProfile": {
                "id": 672,
                "profileName": "EZH2 Y641N"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6564,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with DZNeP resulted in a slight increase in number of dead or sub-G1 cells and accumulation of DNA damage in a diffuse large B-cell lymphoma cell line harboring EZH2 Y641S in culture (PMID: 25605023).",
            "molecularProfile": {
                "id": 673,
                "profileName": "EZH2 Y641S"
            },
            "therapy": {
                "id": 2702,
                "therapyName": "DZNeP",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6565,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DZNeP treatment resulted in an increase in the number of dead or sub-G1 cells and increased DNA damage in a diffuse large B-cell lymphoma cell line harboring EZH2 Y641N in culture (PMID: 25605023).",
            "molecularProfile": {
                "id": 672,
                "profileName": "EZH2 Y641N"
            },
            "therapy": {
                "id": 2702,
                "therapyName": "DZNeP",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6625,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DLBCL cells harboring EZH2 Y641N treated with the combination of ACY-957 and Adriamycin (doxorubicin) resulted in a greater sensitivity to cell death compared to treatment with either agent alone (PMID: 25605023).",
            "molecularProfile": {
                "id": 672,
                "profileName": "EZH2 Y641N"
            },
            "therapy": {
                "id": 4187,
                "therapyName": "ACY-957 + Doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6951,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tazemetostat (EPZ-6438) treatment in non-Hodgkin lymphoma (NHL) patients carrying wild-type EZH2 or an EZH2 Y646H mutation resulted in an objective response rate of 56% (5/9) among patients with diffuse large B-cell lymphoma (ASH 57th Annual Meeting and Exposition, Dec 2015, Abstract #473; NCT01897571).",
            "molecularProfile": {
                "id": 24158,
                "profileName": "EZH2 positive"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5984,
                    "pubMedId": null,
                    "title": "Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients",
                    "url": "http://www.bloodjournal.org/content/126/23/473?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7236,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DLBCL cells expressing BCL6 demonstrated sensitivity to treatment with RI-BPI in culture and in xenograft models, resulting in decreased cell survival and reduced tumor burden (PMID: 18927431).",
            "molecularProfile": {
                "id": 18649,
                "profileName": "BCL6 positive"
            },
            "therapy": {
                "id": 4425,
                "therapyName": "RI-BPI",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6245,
                    "pubMedId": 18927431,
                    "title": "A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18927431"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7270,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, diffuse large B-cell lymphoma cells harboring CD79B Y196F demonstrated sensitivity to treatment with Sotrastaurin (AEB071) in culture and in vivo, resulting in down regulation of NF-kB signaling, cell death, and inhibition of tumor growth (PMID: 21324920).",
            "molecularProfile": {
                "id": 24814,
                "profileName": "CD79B Y196F"
            },
            "therapy": {
                "id": 621,
                "therapyName": "AEB071",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3976,
                    "pubMedId": 21324920,
                    "title": "Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21324920"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7271,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, diffuse large B-cell lymphoma cells harboring CD79B Y196F demonstrated sensitivity to treatment with Sotrastaurin (AEB071) in culture and in vivo, resulting in down regulation of NF-kB signaling, cell death, and inhibition of tumor growth (PMID: 21324920).",
            "molecularProfile": {
                "id": 24815,
                "profileName": "CD79B Y196H"
            },
            "therapy": {
                "id": 621,
                "therapyName": "AEB071",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3976,
                    "pubMedId": 21324920,
                    "title": "Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21324920"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7345,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a diffuse large B-cell lymphoma cell line harboring a CD79A activating mutation demonstrated sensitivity to treatment with Sotrastaurin (AEB071), resulting in decreased cell growth (PMID: 21324920).",
            "molecularProfile": {
                "id": 14364,
                "profileName": "CD79A act mut"
            },
            "therapy": {
                "id": 621,
                "therapyName": "AEB071",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3976,
                    "pubMedId": 21324920,
                    "title": "Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21324920"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7346,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a diffuse large B-cell lymphoma cell line harboring a CD79A activating mutation demonstrated sensitivity to treatment with BHA536, resulting in decreased cell growth (PMID: 21324920).",
            "molecularProfile": {
                "id": 14364,
                "profileName": "CD79A act mut"
            },
            "therapy": {
                "id": 4475,
                "therapyName": "BHA536",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3976,
                    "pubMedId": 21324920,
                    "title": "Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21324920"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8357,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with CPI-0610 resulted in a complete response in two patients with diffuse large B-cell lymphoma (Blood 2015 126:1491).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2033,
                "therapyName": "CPI-0610",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6630,
                    "pubMedId": null,
                    "title": "BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study",
                    "url": "http://www.bloodjournal.org/content/126/23/1491"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8805,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FX1 inhibited growth of Bcl6-dependent diffuse large B-cell lymphoma cell lines in culture and induced tumor shrinkage in cell line xenograft models (PMID: 27482887).",
            "molecularProfile": {
                "id": 18649,
                "profileName": "BCL6 positive"
            },
            "therapy": {
                "id": 4815,
                "therapyName": "FX1",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6759,
                    "pubMedId": 27482887,
                    "title": "Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27482887"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8806,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FX1 enhanced response to Adriamycin (doxorubicin) in both germinal center B cell and activated B cell subtypes of diffuse large B-cell lymphoma cell lines in culture (PMID: 27482887).",
            "molecularProfile": {
                "id": 18649,
                "profileName": "BCL6 positive"
            },
            "therapy": {
                "id": 4816,
                "therapyName": "Doxorubicin + FX1",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6759,
                    "pubMedId": 27482887,
                    "title": "Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27482887"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9131,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD5153 inhibited proliferation of diffuse large B-cell lymphoma cells harboring BCL2 mutation in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27573426).",
            "molecularProfile": {
                "id": 26746,
                "profileName": "BCL2 mutant"
            },
            "therapy": {
                "id": 4910,
                "therapyName": "AZD5153",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6927,
                    "pubMedId": 27573426,
                    "title": "AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27573426"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9420,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Brukinsa (zanubrutinib) inhibited BTK signaling and proliferation of diffuse large B-cell lymphoma (DLBCL) cell lines in culture, and demonstrated antitumor activity in a DLBCL cell line xenograft model, with improved efficacy compared to Imbruvica (ibrutinib) (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2597).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2544,
                "therapyName": "Zanubrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7182,
                    "pubMedId": null,
                    "title": "BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/2597"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9870,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, diffuse large B-cell lymphoma cell lines demonstrated sensitivity to GS-5829 treatment in culture, resulting in inhibition of cell growth, decreased Myc protein expression, and apoptotic activity (Blood 2016 128:5104).",
            "molecularProfile": {
                "id": 15187,
                "profileName": "MYC positive"
            },
            "therapy": {
                "id": 5276,
                "therapyName": "GS-5829",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7727,
                    "pubMedId": null,
                    "title": "Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines",
                    "url": "http://www.bloodjournal.org/content/128/22/5104?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9871,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, diffuse large B-cell lymphoma cell lines highly expressing Bcl2 demonstrated sensitivity to Venclexta (venetoclax) in culture, resulting in inhibition of cell growth (Blood 2016 128:5104).",
            "molecularProfile": {
                "id": 26142,
                "profileName": "BCL2 positive"
            },
            "therapy": {
                "id": 1562,
                "therapyName": "Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7727,
                    "pubMedId": null,
                    "title": "Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines",
                    "url": "http://www.bloodjournal.org/content/128/22/5104?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9873,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, diffuse large B-cell lymphoma cell lines demonstrated greater cell growth inhibition when treated with a combination of GS-5829 and Venclexta (venetoclax) compared to either agent alone in culture (Blood 2016 128:5104).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5277,
                "therapyName": "GS-5829 + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7727,
                    "pubMedId": null,
                    "title": "Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines",
                    "url": "http://www.bloodjournal.org/content/128/22/5104?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9914,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CUDC-907 inhibited growth of diffuse large B-cell lymphoma (DLBCL) cell lines harboring MYC translocations in culture, and reduced MYC expression and tumor growth in a DLBCL cell line xenograft model harboring a MYC translocation (PMID: 27980108).",
            "molecularProfile": {
                "id": 15360,
                "profileName": "MYC rearrange"
            },
            "therapy": {
                "id": 709,
                "therapyName": "CUDC-907",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7758,
                    "pubMedId": 27980108,
                    "title": "Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27980108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9916,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CUDC-907 inhibited growth of diffuse large B-cell lymphoma cell lines with MYC amplification in culture (PMID: 27980108).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 709,
                "therapyName": "CUDC-907",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7758,
                    "pubMedId": 27980108,
                    "title": "Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27980108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9921,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, diffuse large B-cell lymphoma cells treated with RXC005 in culture, demonstrated inhibition of BTK signaling and decreased cell growth (Blood 2016 128:4399).",
            "molecularProfile": {
                "id": 2293,
                "profileName": "BTK positive"
            },
            "therapy": {
                "id": 5298,
                "therapyName": "RXC005",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7759,
                    "pubMedId": null,
                    "title": "REDX08608, a Novel, Potent and Selective, Reversible BTK Inhibitor with Efficacy and Equivalent Potency Against Wild-Type and Mutant C481S BTK",
                    "url": "http://www.bloodjournal.org/content/128/22/4399?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9996,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the mouse surrogate version of TTI-621 (SIRPalpha-Fc) decreased tumor growth in a diffuse large B-cell lymphoma cell line xenograft model (PMID: 27856600).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5338,
                "therapyName": "TTI-621",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7888,
                    "pubMedId": 27856600,
                    "title": "TTI-621 (SIRP\u03b1Fc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27856600"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10003,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 79-6 inhibited viability of BCL6-dependent diffuse large B-cell lymphoma (DLBCL) cell lines and BCL6-expressing primary DLBCL cells in culture, and reduced tumor volume and increased apoptosis in BCL6-dependent DLBCL cell line xenograft models (PMID: 20385364).",
            "molecularProfile": {
                "id": 18649,
                "profileName": "BCL6 positive"
            },
            "therapy": {
                "id": 5339,
                "therapyName": "79-6",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7892,
                    "pubMedId": 20385364,
                    "title": "A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20385364"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10219,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, patients with diffuse large B-cell lymphoma demonstrated an overall response rate of 31% (5/16) and a median duration response of 1.9 months when treated with Abexinostat (PCI-24781) (PMID: 28126962).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1081,
                "therapyName": "Abexinostat",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8169,
                    "pubMedId": 28126962,
                    "title": "Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28126962"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10340,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a diffuse large B-cell lymphoma cell line harboring MYD88 L256P demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased apoptosis (PMID: 27733371).",
            "molecularProfile": {
                "id": 6507,
                "profileName": "MYD88 L265P"
            },
            "therapy": {
                "id": 1077,
                "therapyName": "Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8322,
                    "pubMedId": 27733371,
                    "title": "TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27733371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10745,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Calquence (acalabrutinib) and ACP-319 resulted in decreased tumor volume in diffuse large B-cell lymphoma xenograft models (Eur J of Cancer, Dec 2016, 69;1, S39-S40).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5466,
                "therapyName": "Acalabrutinib + ACP-319",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8797,
                    "pubMedId": null,
                    "title": "The novel BTK and PI3K-delta inhibitors acalabrutinib (ACP-196) and ACP-319 show activity in pre-clinical B-cell lymphoma models",
                    "url": "http://www.ejcancer.com/article/S0959-8049(16)32699-5/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10803,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AT-7867 inhibited the growth of diffuse large B-cell lymphoma cell lines in culture (PMID: 26824321).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2447,
                "therapyName": "AT-7867",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8836,
                    "pubMedId": 26824321,
                    "title": "Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26824321"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10958,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with diffuse large B-cell lymphoma demonstrated a partial response when treated with OPB-111077 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B118).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5739,
                "therapyName": "OPB-111077",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8960,
                    "pubMedId": null,
                    "title": "Abstract B118: A phase 1, open-label multiple dose escalation trial to determine safety and tolerability of once daily OPB-111077 in subjects with advanced cancer",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/B118.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11143,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y646F demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture (PMID: 28135235).",
            "molecularProfile": {
                "id": 29841,
                "profileName": "EZH2 Y646F"
            },
            "therapy": {
                "id": 5886,
                "therapyName": "EED226",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9115,
                    "pubMedId": 28135235,
                    "title": "An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28135235"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11144,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y646N demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture (PMID: 28135235).",
            "molecularProfile": {
                "id": 1175,
                "profileName": "EZH2 Y646N"
            },
            "therapy": {
                "id": 5886,
                "therapyName": "EED226",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9115,
                    "pubMedId": 28135235,
                    "title": "An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28135235"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11145,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y641N demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture and delayed tumor growth and tumor regression in a cell line xenograft model (PMID: 28135235).",
            "molecularProfile": {
                "id": 672,
                "profileName": "EZH2 Y641N"
            },
            "therapy": {
                "id": 5886,
                "therapyName": "EED226",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9115,
                    "pubMedId": 28135235,
                    "title": "An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28135235"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11146,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y646S demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture (PMID: 28135235).",
            "molecularProfile": {
                "id": 29843,
                "profileName": "EZH2 Y646S"
            },
            "therapy": {
                "id": 5886,
                "therapyName": "EED226",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9115,
                    "pubMedId": 28135235,
                    "title": "An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28135235"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11147,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, diffuse large B-cell lymphoma cells co-expressing EZH2 F120L and EZH2 Y111N were resistant to EI1 in culture, demonstrating no inhibition of cell proliferation (PMID: 28135235).",
            "molecularProfile": {
                "id": 27920,
                "profileName": "EZH2 Y111N EZH2 F120L"
            },
            "therapy": {
                "id": 2927,
                "therapyName": "EI1",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9115,
                    "pubMedId": 28135235,
                    "title": "An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28135235"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11149,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, diffuse large B-cell lymphoma cells co-expressing EZH2 F120L and EZH2 Y111N were sensitive to EED226, demonstrating inhibition of cell proliferation in culture (PMID: 28135235).",
            "molecularProfile": {
                "id": 27920,
                "profileName": "EZH2 Y111N EZH2 F120L"
            },
            "therapy": {
                "id": 5886,
                "therapyName": "EED226",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9115,
                    "pubMedId": 28135235,
                    "title": "An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28135235"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11151,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EED226 and EI1 synergistically inhibited cell proliferation in a diffuse large B-cell lymphoma cell line harboring EZH2 Y641N in culture (PMID: 28135235).",
            "molecularProfile": {
                "id": 672,
                "profileName": "EZH2 Y641N"
            },
            "therapy": {
                "id": 5887,
                "therapyName": "EED226 + EI1",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9115,
                    "pubMedId": 28135235,
                    "title": "An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28135235"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11161,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a diffuse large B-cell lymphoma cell line harboring an EZH2 mutation demonstrated sensitivity to A-395, showing inhibition of tumor growth, however, due to its chemical properties A-395 will not proceed to clinical development (PMID: 28135237).",
            "molecularProfile": {
                "id": 27863,
                "profileName": "EZH2 mutant"
            },
            "therapy": {
                "id": 5889,
                "therapyName": "A-395",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9122,
                    "pubMedId": 28135237,
                    "title": "The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28135237"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11402,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Imbruvica (ibrutinib) and Venclexta (venetoclax) resulted in a synergistic effect, demonstrating growth suppression in germinal center B-cell diffuse large B-cell lymphoma (DLBCL) cell lines in culture, increased apoptotic activity and inhibition of colony formation in activated B-cell (ABC) DLBCL cell lines, and complete tumor growth inhibition in ABC-DLBCL cell line xenograft models (PMID: 28428442).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3392,
                "therapyName": "Ibrutinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9292,
                    "pubMedId": 28428442,
                    "title": "Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28428442"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11431,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK C481S resulting in Imbruvica (ibrutinib) resistance demonstrated increased sensitivity to Imbruvica (ibrutinib) when also treated with Venclexta (venetoclax), demonstrating decreased cell growth in culture (PMID: 28428442).",
            "molecularProfile": {
                "id": 2309,
                "profileName": "BTK C481S"
            },
            "therapy": {
                "id": 3392,
                "therapyName": "Ibrutinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9292,
                    "pubMedId": 28428442,
                    "title": "Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28428442"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11791,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Fenretinide treatment resulted in partial response in a patient with diffuse large B-cell lymphoma (PMID:28420721).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2731,
                "therapyName": "Fenretinide",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9767,
                    "pubMedId": 28420721,
                    "title": "Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28420721"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11862,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, treatment with JCAR017 resulted in complete remission and durable central nervous system response in a patient with diffuse large B-cell lymphoma (PMID: 28834486).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5980,
                "therapyName": "JCAR017",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9882,
                    "pubMedId": 28834486,
                    "title": "Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28834486"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11869,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the TNFAIP3 Q143* mutation was identified in diffuse large B-cell lymphoma cells that acquired resistance to Imbruvica (ibrutinib) in culture (PMID: 28178345).",
            "molecularProfile": {
                "id": 28333,
                "profileName": "TNFAIP3 Q143*"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9819,
                    "pubMedId": 28178345,
                    "title": "PI3K\u03b4 inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K\u03b4 and BTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28178345"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11870,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the BTK C481F mutation was identified in diffuse large B-cell lymphoma cells that acquired resistance to Imbruvica (ibrutinib) in culture (PMID: 28178345).",
            "molecularProfile": {
                "id": 1835,
                "profileName": "BTK C481F"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9819,
                    "pubMedId": 28178345,
                    "title": "PI3K\u03b4 inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K\u03b4 and BTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28178345"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11872,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, diffuse large B-cell lymphoma cells that acquired resistance to Imbruvica (ibrutinib) harbored the BTK C481F mutation, and was resistant to ONO-4059 in culture (PMID: 28178345).",
            "molecularProfile": {
                "id": 1835,
                "profileName": "BTK C481F"
            },
            "therapy": {
                "id": 2691,
                "therapyName": "ONO-4059",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9819,
                    "pubMedId": 28178345,
                    "title": "PI3K\u03b4 inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K\u03b4 and BTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28178345"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11873,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, diffuse large B-cell lymphoma cells with acquired resistance to Imbruvica (ibrutinib) harbored the TNFAIP3 Q143* variant and were resistant to ONO-4059 in culture (PMID: 28178345).",
            "molecularProfile": {
                "id": 28333,
                "profileName": "TNFAIP3 Q143*"
            },
            "therapy": {
                "id": 2691,
                "therapyName": "ONO-4059",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9819,
                    "pubMedId": 28178345,
                    "title": "PI3K\u03b4 inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K\u03b4 and BTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28178345"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11874,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, diffuse large B-cell lymphoma cells that acquired resistance to Imbruvica (ibrutinib) harbored the TNFAIP3 Q143* mutation, and was resistant to Zydelig (idelalisib) in culture (PMID: 28178345).",
            "molecularProfile": {
                "id": 28333,
                "profileName": "TNFAIP3 Q143*"
            },
            "therapy": {
                "id": 1023,
                "therapyName": "Idelalisib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9819,
                    "pubMedId": 28178345,
                    "title": "PI3K\u03b4 inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K\u03b4 and BTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28178345"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11876,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, diffuse large B-cell lymphoma cells that acquired resistance to Imbruvica (ibrutinib) harbored the BTK C481F mutation, and was resistant to Zydelig (idelalisib) in culture (PMID: 28178345).",
            "molecularProfile": {
                "id": 1835,
                "profileName": "BTK C481F"
            },
            "therapy": {
                "id": 1023,
                "therapyName": "Idelalisib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9819,
                    "pubMedId": 28178345,
                    "title": "PI3K\u03b4 inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K\u03b4 and BTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28178345"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11878,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, diffuse large B-cell lymphoma cells that acquired resistance to Imbruvica (ibrutinib) harbored the BTK C481F mutation, and was resistant to Zydelig (idelalisib) and ONO-4059 combination treatment in culture (PMID: 28178345).",
            "molecularProfile": {
                "id": 1835,
                "profileName": "BTK C481F"
            },
            "therapy": {
                "id": 6199,
                "therapyName": "Idelalisib + ONO-4059",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9819,
                    "pubMedId": 28178345,
                    "title": "PI3K\u03b4 inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K\u03b4 and BTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28178345"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11879,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zydelig (idelalisib) and ONO-4059, in combination, inhibited growth of diffuse large B-cell lymphoma cells harboring TNFAIP3 Q143* with acquired resistance to Imbruvica (ibrutinib), in culture (PMID: 28178345).",
            "molecularProfile": {
                "id": 28333,
                "profileName": "TNFAIP3 Q143*"
            },
            "therapy": {
                "id": 6199,
                "therapyName": "Idelalisib + ONO-4059",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9819,
                    "pubMedId": 28178345,
                    "title": "PI3K\u03b4 inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K\u03b4 and BTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28178345"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11887,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK2206 partially restored sensitivity to Zydelig (idelalisib) in diffuse large B-cell lymphoma cells harboring PTEN loss with acquired resistance to Zydelig (idelalisib), resulting in increased apoptosis in culture (PMID: 28178345).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 6200,
                "therapyName": "Idelalisib + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9819,
                    "pubMedId": 28178345,
                    "title": "PI3K\u03b4 inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K\u03b4 and BTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28178345"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11890,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2334470 partially restored sensitivity to Zydelig (idelalisib) in diffuse large B-cell lymphoma cells harboring PTEN loss that acquired resistance to Zydelig (idelalisib), resulting in increased apoptosis in culture (PMID: 28178345).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 6201,
                "therapyName": "GSK2334470 + Idelalisib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9819,
                    "pubMedId": 28178345,
                    "title": "PI3K\u03b4 inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K\u03b4 and BTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28178345"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12083,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, the combination treatment of Gazyva (obinutuzumab) with CHOP did not result in an improved 3-year progression free survival rate (70% vs 67%) compared to Rituxan (rituximab) combined with CHOP in patients with diffuse large B-cell lymphoma (PMID: 28796588).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6257,
                "therapyName": "Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine",
                "synonyms": "Obinutuzumab + CHOP"
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10019,
                    "pubMedId": 28796588,
                    "title": "Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28796588"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12116,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Umbralisib (TGR-1202) treatment resulted in objective response in 31% (4/13) and stable disease in 15% (2/13) of patients with diffuse large B-cell lymphoma (PMID: 29475723; NCT01767766).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2022,
                "therapyName": "Umbralisib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11343,
                    "pubMedId": 29475723,
                    "title": "Umbralisib, a novel PI3K\u03b4 and casein kinase-1\u03b5 inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29475723"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12131,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Silmitasertib (CX-4945) and Fostamatinib (R788) worked synergistically to decrease cell viability and resulted in increased apoptosis and decreased AKT phosphorylation in ABC and GCB-type diffuse large B-cell lymphoma cell lines in culture (PMID: 28460620).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6308,
                "therapyName": "Fostamatinib + Silmitasertib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10106,
                    "pubMedId": 28460620,
                    "title": "CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28460620"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12132,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Silmitasertib (CX-4945) and Imbruvica (ibrutinib) worked synergistically to decrease cell viability and resulted in increased apoptosis and decreased AKT phosphorylation in ABC and GCB-type diffuse large B-cell lymphoma cell lines in culture (PMID: 28460620).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6307,
                "therapyName": "Ibrutinib + Silmitasertib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10106,
                    "pubMedId": 28460620,
                    "title": "CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28460620"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12252,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Imbruvica (ibrutinib) treatment demonstrated preferential efficacy in the ABC subtype of diffuse large B-cell lymphoma (DLBCL) compared to the GCB subtype, resulted in complete response in 8% (2/25) and partial response in 32% (8/25) of ABC DLBCL patients, but only partial response in 5.3% (1/19) of GCB DLBCL patients (Blood 2012, 120 (21): 686).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10215,
                    "pubMedId": null,
                    "title": "The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study",
                    "url": "http://www.bloodjournal.org/content/120/21/686?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12253,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, all of diffuse large B-cell lymphoma patients harboring MYD88 L265P (n=4) did not respond to Imbruvica (ibrutinib) treatment (Blood 2012, 120 (21): 686).",
            "molecularProfile": {
                "id": 6507,
                "profileName": "MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10215,
                    "pubMedId": null,
                    "title": "The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study",
                    "url": "http://www.bloodjournal.org/content/120/21/686?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12254,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, all the diffuse large B-cell lymphoma patients harboring both MYD88 L265P and CD79B mutations (n=4) responded to Imbruvica (ibrutinib) treatment (Blood 2012, 120 (21): 686).",
            "molecularProfile": {
                "id": 28604,
                "profileName": "CD79B mut MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10215,
                    "pubMedId": null,
                    "title": "The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study",
                    "url": "http://www.bloodjournal.org/content/120/21/686?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12298,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with SNS-510 decreased PDPK1 pathway signaling and proliferation of a diffuse large B-cell lymphoma cell line in culture (Mol Cancer Ther, Dec 1 2015 (14) (12 Supplement 2) C198).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6432,
                "therapyName": "SNS-510",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10296,
                    "pubMedId": null,
                    "title": "Abstract C198: PDK1 inhibitors SNS-229 and SNS-510 cause pathway modulation, apoptosis and tumor regression in hematologic cancer models in addition to solid tumors",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/C198"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12560,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (JULIET) that supported FDA approval, Kymriah (tisagenlecleucel) treatment resulted in an overall response rate of 50% (34/68) , with complete response in 32% (22/68) and partial response in 18% (12/68) of patients with diffuse large B-cell lymphoma (ASH, 59th Annual Meeting and Exposition, Dec 2017, Abstract 577; NCT02445248).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5981,
                "therapyName": "Tisagenlecleucel",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10432,
                    "pubMedId": null,
                    "title": "Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
                    "url": "https://ash.confex.com/ash/2017/webprogram/Paper105399.html"
                },
                {
                    "id": 15673,
                    "pubMedId": null,
                    "title": "Kymriah (tisagenlecleucel) FDA Drug Label",
                    "url": "https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13562,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of PQR309 and Imbruvica (ibrutinib) led to a synergistic effect in 6/7 diffuse large B-cell lymphoma (DLBCL) cell lines in culture, and the effect was confirmed in a DLBCL cell line xenograft model (PMID: 29066507).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6840,
                "therapyName": "Ibrutinib + PQR309",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11163,
                    "pubMedId": 29066507,
                    "title": "PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29066507"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13591,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, LAM-002A demonstrated safety and preliminary efficacy, resulted in systemic partial metabolic responses and decreased tumor size in 3 of 11 patients with diffuse large B-cell lymphoma (Blood 2017 130 (Suppl 1):4119).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6848,
                "therapyName": "LAM-002A",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11215,
                    "pubMedId": null,
                    "title": "Phase 1 Clinical Safety, Pharmacokinetics (PK), and Activity of Apilimod Dimesylate (LAM-002A), a First-in-Class Inhibitor of Phosphatidylinositol-3-Phosphate 5-Kinase (PIKfyve), in Patients with Relapsed or Refractory B-Cell Malignancies",
                    "url": "http://www.bloodjournal.org/content/130/Suppl_1/4119"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14313,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Buparlisib (BKM120) and Imbruvica (ibrutinib) combination treatment resulted in a best overall response rate of 31% (4/13, 3 complete response, 1 partial response) in patients with relapsed/refractory diffuse large B-cell lymphoma (J Clin Oncol 36, 2018 (suppl; abstr 7520); NCT02756247).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3630,
                "therapyName": "Buparlisib + Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11582,
                    "pubMedId": null,
                    "title": "Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.",
                    "url": "http://abstracts.asco.org/214/AbstView_214_229221.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14532,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EBI-2511 treatment in diffuse large B-cell lymphoma cell line xenograft models resulted in tumor growth inhibition and a 97% decrease in tumor size (PMID: 29456795).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7165,
                "therapyName": "EBI-2511",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11732,
                    "pubMedId": 29456795,
                    "title": "Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin's Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29456795"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15001,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Loncastuximab tesirine treatment resulted in an objective response rate of 57.1% (20/35) with a complete response rate of 34.3% (12/35) in patients with diffuse large B-cell lymphoma (Blood 2017 130(Suppl 1):187, NCT02669017).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7372,
                "therapyName": "Loncastuximab tesirine",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 12057,
                    "pubMedId": null,
                    "title": "Encouraging Early Results from the First in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory B-Cell Lineage Non-Hodgkin Lymphoma",
                    "url": "http://www.bloodjournal.org/content/130/Suppl_1/187"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15070,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, STRO-001 potently inhibited growth of diffuse large B-cell lymphoma cell lines in culture, and suppressed tumor growth in cell line xenograft models (Blood 2016 128 (22):464).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7413,
                "therapyName": "STRO-001",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 12622,
                    "pubMedId": null,
                    "title": "Targeting CD74 with Novel Antibody Drug Conjugates (ADCs) for the Treatment of B-Cell Non-Hodgkin's Lymphoma (NHL)",
                    "url": "http://www.bloodjournal.org/content/128/22/464?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16079,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib study, combined Hu5F9-G4 and Rituxan (rituximab) therapy demonstrated safety and efficacy, resulting in an objective response rate of 40% (6/15, 5 complete and 1 partial response) and stable disease in 20% (3/15) of patients with diffuse large B-cell lymphoma, and a median duration of response longer than 6 months (PMID: 30380386).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4955,
                "therapyName": "Hu5F9-G4 + Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14206,
                    "pubMedId": 30380386,
                    "title": "CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30380386"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16708,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AGS67E inhibited growth of CD37-positive diffuse large B-cell lymphoma cell lines in culture, and inhibited tumor growth in xenograft models (PMID: 25934707).",
            "molecularProfile": {
                "id": 30535,
                "profileName": "CD37 positive"
            },
            "therapy": {
                "id": 8154,
                "therapyName": "AGS67E",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14736,
                    "pubMedId": 25934707,
                    "title": "AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25934707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17275,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II (GO29365) trial that supported FDA approval, addition of Polivy (polatuzumab vedotin-piiq) to Treanda (bendamustine) and Rituxan (rituximab) combination (BR) therapy resulted in improved complete response rate (40% vs 18%) and best overall response rate (63% vs 25%) compared to BR therapy alone in patients with relapsed or refractory diffuse large B-cell lymphoma (Blood 2017 130:2821; NCT02257567).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7624,
                "therapyName": "Bendamustine + Polatuzumab vedotin-piiq + Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15309,
                    "pubMedId": null,
                    "title": "Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study",
                    "url": "http://www.bloodjournal.org/content/130/Suppl_1/2821"
                },
                {
                    "id": 15668,
                    "pubMedId": null,
                    "title": "Polivy (polatuzumab vedotin-piiq) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761121"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17575,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, Rituxan (rituximab) treatment as induction or maintenance therapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) significantly improved 2-year progression-free survival rate (76% vs 61%, p=0.009) compared to CHOP alone in elderly patients with untreated, MS4A1 (CD20)-positive, diffuse large B-cell lymphoma (PMID: 16754935).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 2195,
                "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine",
                "synonyms": "Rituximab + CHOP|RCHOP"
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15611,
                    "pubMedId": null,
                    "title": "Rituxan (rituximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705"
                },
                {
                    "id": 15645,
                    "pubMedId": 16754935,
                    "title": "Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16754935"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17574,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (MInT) that supported FDA approval, Rituxan (rituximab) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy resulted in improved 3-year event-free survival (79% vs 59%) and 3-year overall survival (93% vs 84%) compared to chemotherapy alone in patients with untreated, MS4A1 (CD20)-positive, diffuse large B-cell lymphoma with good prognosis (PMID: 16648042; NCT00064116).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 2195,
                "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine",
                "synonyms": "Rituximab + CHOP|RCHOP"
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15611,
                    "pubMedId": null,
                    "title": "Rituxan (rituximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705"
                },
                {
                    "id": 15644,
                    "pubMedId": 16648042,
                    "title": "CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16648042"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18451,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MEN1309 treatment reduced tumor volume in a cell line xenograft model of diffuse large B-cell lymphoma with heterogeneous LY75 expression (PMID: 31227646).",
            "molecularProfile": {
                "id": 33235,
                "profileName": "LY75 positive"
            },
            "therapy": {
                "id": 8717,
                "therapyName": "MEN1309",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16207,
                    "pubMedId": 31227646,
                    "title": "MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227646"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18737,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, APG-2575 and Imbruvica (ibrutinib) combination therapy exhibited synergistic antitumor activity and induced tumor regression (80% complete and 20% partial) in cell-line xenograft models of diffuse large B-cell lymphoma (Cancer Res July 1 2019 (79) (13 Supplement) 2058).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8826,
                "therapyName": "APG-2575 + Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16405,
                    "pubMedId": null,
                    "title": "BCL-2 selective inhibitor APG-2575 synergizes with BTK inhibitor in preclinical xenograft models of follicular lymphoma and diffuse large B-cell lymphoma",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/2058"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19069,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY-8002 inhibited proliferation of a SLC16A1-positive diffuse large B-cell lymphoma cell line in culture, however, did not reduce tumor growth in a cell line xenograft model (PMID: 30115664).",
            "molecularProfile": {
                "id": 28744,
                "profileName": "SLC16A1 positive"
            },
            "therapy": {
                "id": 8690,
                "therapyName": "BAY-8002",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16079,
                    "pubMedId": 30115664,
                    "title": "Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30115664"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19070,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3965 inhibited proliferation of a SLC16A1-positive diffuse large B-cell lymphoma cell line in culture, however, did not significantly inhibit tumor growth in a cell line xenograft model (PMID: 30115664).",
            "molecularProfile": {
                "id": 28744,
                "profileName": "SLC16A1 positive"
            },
            "therapy": {
                "id": 653,
                "therapyName": "AZD3965",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16079,
                    "pubMedId": 30115664,
                    "title": "Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30115664"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19113,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "MYC rearrangement aids in the diagnosis of adult and pediatric diffuse large B-cell lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 15360,
                "profileName": "MYC rearrange"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19114,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "BCL2 rearrangement aids in the diagnosis of adult and pediatric diffuse large B-cell lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 15361,
                "profileName": "BCL2 rearrange"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19115,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "BCL6 rearrangement aids in the diagnosis of adult and pediatric diffuse large B-cell lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 15362,
                "profileName": "BCL6 rearrange"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19122,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Adcentris (brentuximab vedotin) is included in guidelines as a second-line and subsequent therapy for patients with TNFRSF8 (CD30)-positive diffuse large B-cell lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 23635,
                "profileName": "TNFRSF8 positive"
            },
            "therapy": {
                "id": 1231,
                "therapyName": "Bendamustine",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19551,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, diffuse large B-cell lymphoma cell lines harboring EZH2 mutations demonstrated increased sensitivity to Tazemetostat (EPZ-6438) treatment-induced growth inhibition, apoptosis, and tumor inhibition compared to EZH2 wild-type cell lines (PMID: 28835384).",
            "molecularProfile": {
                "id": 27863,
                "profileName": "EZH2 mutant"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17174,
                    "pubMedId": 28835384,
                    "title": "EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28835384"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19552,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tazemetostat (EPZ-6438) and Mekinist (trametinib) synergistically inhibited proliferation of diffuse large B-cell lymphoma cell lines harboring EZH2 mutations in culture (PMID: 28835384).",
            "molecularProfile": {
                "id": 27863,
                "profileName": "EZH2 mutant"
            },
            "therapy": {
                "id": 9079,
                "therapyName": "Tazemetostat + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17174,
                    "pubMedId": 28835384,
                    "title": "EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28835384"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19553,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tazemetostat (EPZ-6438) and MK-2206 synergistically inhibited proliferation of diffuse large B-cell lymphoma cell lines harboring EZH2 mutations in culture (PMID: 28835384).",
            "molecularProfile": {
                "id": 27863,
                "profileName": "EZH2 mutant"
            },
            "therapy": {
                "id": 4749,
                "therapyName": "MK2206 + Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17174,
                    "pubMedId": 28835384,
                    "title": "EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28835384"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19554,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tazemetostat (EPZ-6438) and Afinitor (everolimus) synergistically inhibited proliferation of diffuse large B-cell lymphoma cell lines harboring EZH2 mutations in culture (PMID: 28835384).",
            "molecularProfile": {
                "id": 27863,
                "profileName": "EZH2 mutant"
            },
            "therapy": {
                "id": 9078,
                "therapyName": "Everolimus + Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17174,
                    "pubMedId": 28835384,
                    "title": "EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28835384"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19555,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tazemetostat (EPZ-6438) and Imbruvica (ibrutinib) synergistically inhibited proliferation of diffuse large B-cell lymphoma cell lines harboring EZH2 mutations in culture (PMID: 28835384).",
            "molecularProfile": {
                "id": 27863,
                "profileName": "EZH2 mutant"
            },
            "therapy": {
                "id": 9080,
                "therapyName": "Ibrutinib + Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17174,
                    "pubMedId": 28835384,
                    "title": "EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28835384"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19556,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tazemetostat (EPZ-6438) and Zydelig (idelalisib) synergistically inhibited proliferation of diffuse large B-cell lymphoma cell lines harboring EZH2 mutations in culture (PMID: 28835384).",
            "molecularProfile": {
                "id": 27863,
                "profileName": "EZH2 mutant"
            },
            "therapy": {
                "id": 9081,
                "therapyName": "Idelalisib + Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17174,
                    "pubMedId": 28835384,
                    "title": "EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28835384"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19557,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tazemetostat (EPZ-6438) and Tamatinib (R406) synergistically inhibited proliferation of diffuse large B-cell lymphoma cell lines harboring EZH2 mutations in culture (PMID: 28835384).",
            "molecularProfile": {
                "id": 27863,
                "profileName": "EZH2 mutant"
            },
            "therapy": {
                "id": 9083,
                "therapyName": "Tamatinib + Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17174,
                    "pubMedId": 28835384,
                    "title": "EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28835384"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19563,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tazemetostat (EPZ-6438) demonstrated safety and preliminary efficacy, resulted in 1 complete response and 3 partial response in patients with relapsed or refractory diffuse large B-cell lymphoma (PMID: 29650362; NCT01897571).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17176,
                    "pubMedId": 29650362,
                    "title": "Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650362"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19564,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tazemetostat (EPZ-6438) treatment resulted in a durable partial response in a patient with diffuse large B-cell lymphoma harboring EZH2 Y646H, and the patient was progression-free for 16 months (PMID: 29650362; NCT01897571).",
            "molecularProfile": {
                "id": 29842,
                "profileName": "EZH2 Y646H"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17176,
                    "pubMedId": 29650362,
                    "title": "Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650362"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19644,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, DRL_RI demonstrated comparable pharmacokinetic, safety, immunogenicity, and efficacy to Rituxan (rituximab) in patients with MS4A1 (CD20)-positive diffuse large B-cell lymphoma, resulted in an overall response rate of 82.0% (50/61), compared to 84.8% (56/66) in Rituxan (rituximab)-treated group (PMID: 31809224).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 9117,
                "therapyName": "DRL_RI",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17384,
                    "pubMedId": 31809224,
                    "title": "Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31809224"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19973,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK3368715 treatment inhibited growth of a diffuse large B-cell lymphoma (DLBCL) cell line in culture and inhibited tumor growth in xenograft models, and inhibited growth of patient-derived DLBCL cells in culture PMID: 31257072).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9261,
                "therapyName": "GSK3368715",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17642,
                    "pubMedId": 31257072,
                    "title": "Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31257072"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19985,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK3203591 and GSK3368715 worked synergistically to inhibit viability of diffuse large B-cell lymphoma cell lines in culture (PMID: 31257072).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9263,
                "therapyName": "GSK3203591 + GSK3368715",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17642,
                    "pubMedId": 31257072,
                    "title": "Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31257072"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20473,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ARV-771 treatment reduced Brd4 expression, and induced apoptosis in ABC-like diffuse large-B-cell lymphoma cell lines harboring copy gains in TCF4 and expressing BRD4 in culture, and inhibited tumor growth in cell line xenograft models (PMID: 31217338).",
            "molecularProfile": {
                "id": 21298,
                "profileName": "BRD4 positive"
            },
            "therapy": {
                "id": 9364,
                "therapyName": "ARV-771",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17851,
                    "pubMedId": 31217338,
                    "title": "Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31217338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20610,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, diffuse large B-cell lymphoma patients tolerated MOR208 treatment, and achieved an overall response rate of 26% (9/35, 2 complete and 7 partial response) with 5 patients responding over 12 months, a disease control rate of 40% (14/35), a median duration of response of 20.1 months and a progression-free survival of 2.7 months at a median follow-up of 21 months (PMID: 29444231; NCT01685008).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5783,
                "therapyName": "MOR208",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17962,
                    "pubMedId": 29444231,
                    "title": "Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29444231"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00001337",
            "title": "Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3395,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00006436",
            "title": "EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9703,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Prednisone + Rituximab + Vincristine",
                    "synonyms": "EPOCH + Filgrastim + Rituximab"
                }
            ]
        },
        {
            "nctId": "NCT00671112",
            "title": "Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2234,
                    "therapyName": "Bortezomib + Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00918463",
            "title": "A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00978432",
            "title": "Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1964,
                    "therapyName": "Everolimus + Panobinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01177397",
            "title": "Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 693,
                    "therapyName": "CC-223",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01193842",
            "title": "Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1077,
                    "therapyName": "Vorinostat",
                    "synonyms": null
                },
                {
                    "id": 3395,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01251575",
            "title": "Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 2270,
                    "therapyName": "Cyclosporine + Mycophenolate mofetil + Sirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01307267",
            "title": "A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 6111,
                    "therapyName": "Rituximab + Utomilumab",
                    "synonyms": null
                },
                {
                    "id": 5086,
                    "therapyName": "Utomilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01334502",
            "title": "Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                },
                {
                    "id": 2195,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Rituximab + CHOP|RCHOP"
                }
            ]
        },
        {
            "nctId": "NCT01421524",
            "title": "Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2358,
                    "therapyName": "CC-122",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01431209",
            "title": "Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 907,
                    "therapyName": "Ruxolitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01449461",
            "title": "A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 634,
                    "therapyName": "Brigatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01453205",
            "title": "A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2354,
                    "therapyName": "Cisplatin + Cytarabine + Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 2352,
                    "therapyName": "Carboplatin + Etoposide + Ifosfamide",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 2407,
                    "therapyName": "MEDI-551",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01686165",
            "title": "Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1078,
                    "therapyName": "Belinostat",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01691898",
            "title": "A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS)",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4415,
                    "therapyName": "Obinutuzumab + Pinatuzumab Vedotin + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 4416,
                    "therapyName": "Pinatuzumab Vedotin + Polatuzumab vedotin-piiq + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 4417,
                    "therapyName": "Obinutuzumab + Polatuzumab vedotin-piiq",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01719250",
            "title": "Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 680,
                    "therapyName": "Buparlisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01742988",
            "title": "Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8587,
                    "therapyName": "Bendamustine + CUDC-907 + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 4447,
                    "therapyName": "CUDC-907 + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 709,
                    "therapyName": "CUDC-907",
                    "synonyms": null
                },
                {
                    "id": 8586,
                    "therapyName": "CUDC-907 + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01799889",
            "title": "A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2522,
                    "therapyName": "Entospletinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01804686",
            "title": "A Long-term Extension Study of PCI-32765 (Ibrutinib)",
            "phase": "Phase III",
            "recruitment": "Enrolling by invitation",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01811368",
            "title": "Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9105,
                    "therapyName": "anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 2272,
                    "therapyName": "Cyclosporine + Mycophenolate mofetil",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01854606",
            "title": "Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1951,
                    "therapyName": "AEB071 + Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01855750",
            "title": "A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 3266,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Vincristine",
                    "synonyms": "CHOP"
                }
            ]
        },
        {
            "nctId": "NCT01859819",
            "title": "Treatment for Advanced B-Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6875,
                    "therapyName": "Cytarabine + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01897012",
            "title": "Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1075,
                    "therapyName": "Romidepsin",
                    "synonyms": null
                },
                {
                    "id": 626,
                    "therapyName": "Alisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01938638",
            "title": "Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4027,
                    "therapyName": "BAY1143572",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01953692",
            "title": "A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01955499",
            "title": "Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3580,
                    "therapyName": "Ibrutinib + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01959698",
            "title": "Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2351,
                    "therapyName": "Carfilzomib + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 2352,
                    "therapyName": "Carboplatin + Etoposide + Ifosfamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01992653",
            "title": "A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4248,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 4226,
                    "therapyName": "Polatuzumab vedotin-piiq",
                    "synonyms": null
                },
                {
                    "id": 1646,
                    "therapyName": "Obinutuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01994382",
            "title": "Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2531,
                    "therapyName": "Cerdulatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02000934",
            "title": "A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3146,
                    "therapyName": "TAK-659",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02029443",
            "title": "ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1605,
                    "therapyName": "Acalabrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02031419",
            "title": "Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2376,
                    "therapyName": "CC-122 + CC-292",
                    "synonyms": null
                },
                {
                    "id": 2377,
                    "therapyName": "CC-223 + CC-292",
                    "synonyms": null
                },
                {
                    "id": 2375,
                    "therapyName": "CC-122 + CC-223",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02055820",
            "title": "A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1562,
                    "therapyName": "Venetoclax",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 3266,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Vincristine",
                    "synonyms": "CHOP"
                },
                {
                    "id": 1646,
                    "therapyName": "Obinutuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02061761",
            "title": "Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4197,
                    "therapyName": "Nivolumab + Relatlimab",
                    "synonyms": null
                },
                {
                    "id": 4196,
                    "therapyName": "Relatlimab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02073097",
            "title": "Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2351,
                    "therapyName": "Carfilzomib + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 2353,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Vincristine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02077166",
            "title": "Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1610,
                    "therapyName": "Ibrutinib + Lenalidomide + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02082977",
            "title": "A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2925,
                    "therapyName": "GSK126",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02106091",
            "title": "Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 7390,
                    "therapyName": "AFM11",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02138786",
            "title": "Study of Selinexor (KPT-330) in Patients With Refractory and/or Relapsed Richter's Transformation (RT)",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02141451",
            "title": "ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 6929,
                    "therapyName": "INCB7839 + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02178722",
            "title": "A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4088,
                    "therapyName": "Epacadostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02181218",
            "title": "Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1476,
                    "therapyName": "Pegfilgrastim",
                    "synonyms": null
                },
                {
                    "id": 1075,
                    "therapyName": "Romidepsin",
                    "synonyms": null
                },
                {
                    "id": 1611,
                    "therapyName": "Dexamethasone + Gemcitabine + Oxaliplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02203526",
            "title": "Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1607,
                    "therapyName": "Dexamethasone + Etoposide + Ibrutinib + Pegylated liposomal-doxorubicin + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 712,
                    "therapyName": "Cytarabine",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02208037",
            "title": "Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT02219737",
            "title": "Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                },
                {
                    "id": 3360,
                    "therapyName": "Carboplatin + Etoposide + Ifosfamide + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02220842",
            "title": "A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1975,
                    "therapyName": "Atezolizumab + Obinutuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02226965",
            "title": "Wolverine: PNT2258 for Treatment of Patients With r/r DLBCL",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 2581,
                    "therapyName": "PNT2258",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02227251",
            "title": "Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SADAL)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02229981",
            "title": "An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 3301,
                    "therapyName": "ABC294640",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02252146",
            "title": "Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88L265P Mutation",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2866,
                    "therapyName": "IMO-8400",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02257567",
            "title": "A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2323,
                    "therapyName": "Bendamustine + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 4226,
                    "therapyName": "Polatuzumab vedotin-piiq",
                    "synonyms": null
                },
                {
                    "id": 1646,
                    "therapyName": "Obinutuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02282358",
            "title": "Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3002,
                    "therapyName": "Mocetinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02303392",
            "title": "Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3579,
                    "therapyName": "Ibrutinib + Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02315326",
            "title": "Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02323230",
            "title": "A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 4280,
                    "therapyName": "Cyclophosphamide + DPX-Survivac",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02327078",
            "title": "A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3059,
                    "therapyName": "Epacadostat + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02343536",
            "title": "A Phase 1, Open-label,Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2488,
                    "therapyName": "Cyclophosphamide + Prednisone + Rituximab + Vincristine",
                    "synonyms": "R-CHOP"
                },
                {
                    "id": 651,
                    "therapyName": "Azacitidine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02348216",
            "title": "A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4829,
                    "therapyName": "KTE-C19",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02361346",
            "title": "PK, PD, Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Non-Hodgkin's B-Cell Lymphoma and B-Cell Chronic Lymphocytic Leukemia (MT-3724NHL001)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7831,
                    "therapyName": "MT-3724",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02362997",
            "title": "Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02376699",
            "title": "Safety Study of SEA-CD40 in Cancer Patients",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5781,
                    "therapyName": "Pembrolizumab + SEA-CD40",
                    "synonyms": null
                },
                {
                    "id": 5780,
                    "therapyName": "SEA-CD40",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02391116",
            "title": "Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 995,
                    "therapyName": "Copanlisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02399085",
            "title": "A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5843,
                    "therapyName": "Lenalidomide + MOR208",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02401048",
            "title": "A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2573,
                    "therapyName": "Durvalumab + Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02408042",
            "title": "Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 2352,
                    "therapyName": "Carboplatin + Etoposide + Ifosfamide",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2486,
                    "therapyName": "Brentuximab vedotin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02420795",
            "title": "Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1687,
                    "therapyName": "ONC201",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02436707",
            "title": "Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                },
                {
                    "id": 3391,
                    "therapyName": "Cisplatin + Dexamethasone + Gemcitabine + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02440685",
            "title": "A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 7391,
                    "therapyName": "ASN002",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02443077",
            "title": "Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 3359,
                    "therapyName": "Carmustine + Cytarabine + Etoposide + Melphalan",
                    "synonyms": null
                },
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02445248",
            "title": "Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients (JULIET)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5981,
                    "therapyName": "Tisagenlecleucel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02454270",
            "title": "A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 4166,
                    "therapyName": "JNJ-64052781",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02471911",
            "title": "KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 3360,
                    "therapyName": "Carboplatin + Etoposide + Ifosfamide + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02516553",
            "title": "BI 894999 First in Human Dose Finding Study in Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5884,
                    "therapyName": "BI 894999",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02530125",
            "title": "Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3338,
                    "therapyName": "Pidilizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02531308",
            "title": "Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1031,
                    "therapyName": "Metformin",
                    "synonyms": null
                },
                {
                    "id": 3266,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Vincristine",
                    "synonyms": "CHOP"
                },
                {
                    "id": 1476,
                    "therapyName": "Pegfilgrastim",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02532192",
            "title": "A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 712,
                    "therapyName": "Cytarabine",
                    "synonyms": null
                },
                {
                    "id": 1689,
                    "therapyName": "Fluconazole",
                    "synonyms": null
                },
                {
                    "id": 1078,
                    "therapyName": "Belinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02541565",
            "title": "Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 3266,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Vincristine",
                    "synonyms": "CHOP"
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02543879",
            "title": "Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 7335,
                    "therapyName": "FT-1101",
                    "synonyms": null
                },
                {
                    "id": 7336,
                    "therapyName": "Azacitidine + FT-1101",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02549651",
            "title": "MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023)",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 3098,
                    "therapyName": "AZD9150 + Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02564744",
            "title": "Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6931,
                    "therapyName": "IMGN529 + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02570542",
            "title": "Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1756,
                    "therapyName": "Plerixafor",
                    "synonyms": null
                },
                {
                    "id": 3359,
                    "therapyName": "Carmustine + Cytarabine + Etoposide + Melphalan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02572453",
            "title": "AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 645,
                    "therapyName": "Onalespib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02576990",
            "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Primary Mediastinal Large B-cell Lymphoma (MK-3475-170/KEYNOTE-170)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02580552",
            "title": "Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7304,
                    "therapyName": "MRG-106",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02581631",
            "title": "A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3263,
                    "therapyName": "Brentuximab vedotin + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02589145",
            "title": "Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1164,
                    "therapyName": "Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 3277,
                    "therapyName": "Pyridoxine",
                    "synonyms": null
                },
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 2558,
                    "therapyName": "Busulfan + Melphalan",
                    "synonyms": null
                },
                {
                    "id": 3278,
                    "therapyName": "Enoxaparin",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1077,
                    "therapyName": "Vorinostat",
                    "synonyms": null
                },
                {
                    "id": 2373,
                    "therapyName": "Palifermin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02596971",
            "title": "Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1975,
                    "therapyName": "Atezolizumab + Obinutuzumab",
                    "synonyms": null
                },
                {
                    "id": 3266,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Vincristine",
                    "synonyms": "CHOP"
                },
                {
                    "id": 1231,
                    "therapyName": "Bendamustine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02600897",
            "title": "A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4394,
                    "therapyName": "Lenalidomide + Obinutuzumab + Polatuzumab vedotin-piiq",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02611323",
            "title": "A Study of Obinutuzumab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4227,
                    "therapyName": "Obinutuzumab + Polatuzumab vedotin-piiq + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02624986",
            "title": "A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 4393,
                    "therapyName": "Idasanutlin + Obinutuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02628405",
            "title": "R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6747,
                    "therapyName": "Carboplatin + Etoposide + Ifosfamide + Lenalidomide + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02631044",
            "title": "Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5980,
                    "therapyName": "JCAR017",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02636322",
            "title": "A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2482,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Etoposide + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 1610,
                    "therapyName": "Ibrutinib + Lenalidomide + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 2188,
                    "therapyName": "Prednisone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02650999",
            "title": "Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02658968",
            "title": "Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7393,
                    "therapyName": "Betalutin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02674750",
            "title": "Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 709,
                    "therapyName": "CUDC-907",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02681302",
            "title": "Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence (CPIT001)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02684617",
            "title": "Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) (KEYNOTE-155)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4225,
                    "therapyName": "Dinaciclib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02698189",
            "title": "A Dose Exploration Study With MK-8628 in Participants With Selected Hematologic Malignancies (MK-8628-005)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2034,
                    "therapyName": "Birabresib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02700022",
            "title": "A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 626,
                    "therapyName": "Alisertib",
                    "synonyms": null
                },
                {
                    "id": 3395,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02701673",
            "title": "Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 651,
                    "therapyName": "Azacitidine",
                    "synonyms": null
                },
                {
                    "id": 3277,
                    "therapyName": "Pyridoxine",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1078,
                    "therapyName": "Belinostat",
                    "synonyms": null
                },
                {
                    "id": 1206,
                    "therapyName": "Busulfan",
                    "synonyms": null
                },
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02706405",
            "title": "JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4365,
                    "therapyName": "Cyclophosphamide + Durvalumab + JCAR014",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02729896",
            "title": "A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8255,
                    "therapyName": "Obinutuzumab + Polatuzumab vedotin-piiq + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 4362,
                    "therapyName": "Atezolizumab + Obinutuzumab + Polatuzumab vedotin-piiq",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02734771",
            "title": "A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6932,
                    "therapyName": "Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02743546",
            "title": "Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4167,
                    "therapyName": "Ibrutinib + JNJ-64052781",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02756247",
            "title": "A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3630,
                    "therapyName": "Buparlisib + Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02760485",
            "title": "A Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5151,
                    "therapyName": "Ibrutinib + Itacitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02763254",
            "title": "Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas (CIVIC)",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 7394,
                    "therapyName": "CMD-003",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02763319",
            "title": "A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6897,
                    "therapyName": "Bendamustine + MOR208",
                    "synonyms": null
                },
                {
                    "id": 2323,
                    "therapyName": "Bendamustine + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02776813",
            "title": "Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 7267,
                    "therapyName": "ACTR087 + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02793583",
            "title": "Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma (UNITY-DLBCL)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2022,
                    "therapyName": "Umbralisib",
                    "synonyms": null
                },
                {
                    "id": 2319,
                    "therapyName": "Ublituximab + Umbralisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02815397",
            "title": "DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1031,
                    "therapyName": "Metformin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02874404",
            "title": "TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2044,
                    "therapyName": "Ibrutinib + Umbralisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02875002",
            "title": "Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4826,
                    "therapyName": "Belinostat + Volasertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02900651",
            "title": "Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9055,
                    "therapyName": "MAK683",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02909777",
            "title": "Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 709,
                    "therapyName": "CUDC-907",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02914938",
            "title": "A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6745,
                    "therapyName": "ME-401",
                    "synonyms": null
                },
                {
                    "id": 6746,
                    "therapyName": "ME-401 + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02926833",
            "title": "A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4830,
                    "therapyName": "Atezolizumab + KTE-C19",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02931110",
            "title": "Study of IV CBL0137 in Previously Treated Hematological Subjects",
            "phase": "Phase I",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 3940,
                    "therapyName": "CBL0137",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02950220",
            "title": "Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4917,
                    "therapyName": "Ibrutinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02951156",
            "title": "Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5088,
                    "therapyName": "Avelumab + Azacitidine + Utomilumab",
                    "synonyms": null
                },
                {
                    "id": 5087,
                    "therapyName": "Avelumab + Rituximab + Utomilumab",
                    "synonyms": null
                },
                {
                    "id": 2323,
                    "therapyName": "Bendamustine + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 5090,
                    "therapyName": "Gemcitabine + Oxaliplatin + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 5089,
                    "therapyName": "Avelumab + Bendamustine + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02953509",
            "title": "Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4955,
                    "therapyName": "Hu5F9-G4 + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02961816",
            "title": "Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 3277,
                    "therapyName": "Pyridoxine",
                    "synonyms": null
                },
                {
                    "id": 4976,
                    "therapyName": "Busulfan + Gemcitabine + Melphalan + Panobinostat",
                    "synonyms": null
                },
                {
                    "id": 4977,
                    "therapyName": "Dexamethasone + Filgrastim + Palifermin + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02998476",
            "title": "A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3088,
                    "therapyName": "Parsaclisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03003520",
            "title": "A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5350,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Durvalumab + Lenalidomide + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Durvalumab + R2-CHOP"
                },
                {
                    "id": 5349,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Durvalumab + Prednisone + Rituximab + Vincristine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03015896",
            "title": "Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5239,
                    "therapyName": "Lenalidomide + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03019640",
            "title": "Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6934,
                    "therapyName": "Carmustine + Cytarabine + Etoposide + Filgrastim + Lenalidomide + Melphalan + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03028103",
            "title": "Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5267,
                    "therapyName": "Fluconazole + Tazemetostat",
                    "synonyms": null
                },
                {
                    "id": 5285,
                    "therapyName": "Omeprazole + Repaglinide + Tazemetostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03036904",
            "title": "Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5294,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Venetoclax + Vincristine",
                    "synonyms": "Venetoclax + DA-EPOCH-R"
                }
            ]
        },
        {
            "nctId": "NCT03049449",
            "title": "T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9020,
                    "therapyName": "ATLCAR.CD30 cells",
                    "synonyms": null
                },
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03064867",
            "title": "Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5404,
                    "therapyName": "Carboplatin + Etoposide + Ifosfamide + Rituximab + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03103971",
            "title": "huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9019,
                    "therapyName": "Cyclophosphamide + Fludarabine + HuJCAR014",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03106428",
            "title": "A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5762,
                    "therapyName": "MEDI7247",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03123393",
            "title": "TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3146,
                    "therapyName": "TAK-659",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03135262",
            "title": "A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5646,
                    "therapyName": "Idasanutlin + Rituximab + Venetoclax",
                    "synonyms": null
                },
                {
                    "id": 5644,
                    "therapyName": "Idasanutlin + Obinutuzumab + Venetoclax",
                    "synonyms": null
                },
                {
                    "id": 5645,
                    "therapyName": "Idasanutlin + Obinutuzumab + Rituximab + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03136497",
            "title": "A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5777,
                    "therapyName": "Ibrutinib + Rituximab + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03147885",
            "title": "Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03150329",
            "title": "Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3077,
                    "therapyName": "Pembrolizumab + Vorinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03153462",
            "title": "Axicabtagene Ciloleucel Expanded Access Study",
            "phase": "Expanded access",
            "recruitment": "Available",
            "therapies": [
                {
                    "id": 5098,
                    "therapyName": "Cyclophosphamide + Fludarabine + KTE-C19",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03162536",
            "title": "Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5224,
                    "therapyName": "ARQ 531",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03188965",
            "title": "First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5962,
                    "therapyName": "BAY1895344",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03189836",
            "title": "Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7386,
                    "therapyName": "ACTR707 + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03205046",
            "title": "A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6188,
                    "therapyName": "Acalabrutinib + Vistusertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03207867",
            "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4741,
                    "therapyName": "PBF-509 + Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03220022",
            "title": "Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 6466,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Ibrutinib + Pegfilgrastim + Prednisone + Rituximab + Vincristine",
                    "synonyms": "R-da-EPOCH"
                }
            ]
        },
        {
            "nctId": "NCT03255018",
            "title": "Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extra-Nodal Diffuse Large B-cell Lymphomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03255096",
            "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 6179,
                    "therapyName": "Rituximab + TEN-010 + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03259503",
            "title": "Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1206,
                    "therapyName": "Busulfan",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 1077,
                    "therapyName": "Vorinostat",
                    "synonyms": null
                },
                {
                    "id": 2373,
                    "therapyName": "Palifermin",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                },
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 3277,
                    "therapyName": "Pyridoxine",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03263026",
            "title": "Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2195,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Rituximab + CHOP|RCHOP"
                },
                {
                    "id": 1682,
                    "therapyName": "Enzastaurin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03274492",
            "title": "A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4226,
                    "therapyName": "Polatuzumab vedotin-piiq",
                    "synonyms": null
                },
                {
                    "id": 6177,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 2195,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Rituximab + CHOP|RCHOP"
                }
            ]
        },
        {
            "nctId": "NCT03277729",
            "title": "A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9487,
                    "therapyName": "CD20 CAR T-cells + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03283202",
            "title": "Study of Safety and Efficacy of CC-122 Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6898,
                    "therapyName": "CC-122 + Cyclophosphamide + Prednisone + Rituximab + Vincristine",
                    "synonyms": "CC-122 + R-CHOP"
                }
            ]
        },
        {
            "nctId": "NCT03297424",
            "title": "A Study of PLX2853 in Advanced Malignancies.",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6324,
                    "therapyName": "PLX2853",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03305445",
            "title": "Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03309878",
            "title": "Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Lymphomas",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 7642,
                    "therapyName": "Mogamulizumab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03311958",
            "title": "Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03316573",
            "title": "A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03321643",
            "title": "Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6379,
                    "therapyName": "Atezolizumab + Gemcitabine + Oxaliplatin + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 6380,
                    "therapyName": "Atezolizumab + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03349450",
            "title": "DPX-Survivac and Checkpoint Inhibitor in DLBCL (SPiReL)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5266,
                    "therapyName": "Cyclophosphamide + DPX-Survivac + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 4237,
                    "therapyName": "DPX-Survivac",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03357627",
            "title": "A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6911,
                    "therapyName": "TAK-659 + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03365791",
            "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2887,
                    "therapyName": "LAG525",
                    "synonyms": null
                },
                {
                    "id": 2659,
                    "therapyName": "Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03379493",
            "title": "Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT03391466",
            "title": "A Study Evaluating the Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4829,
                    "therapyName": "KTE-C19",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03418038",
            "title": "Ascorbic Acid and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 2352,
                    "therapyName": "Carboplatin + Etoposide + Ifosfamide",
                    "synonyms": null
                },
                {
                    "id": 3360,
                    "therapyName": "Carboplatin + Etoposide + Ifosfamide + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 2354,
                    "therapyName": "Cisplatin + Cytarabine + Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 6722,
                    "therapyName": "Cisplatin + Dexamethasone + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 6724,
                    "therapyName": "Cytarabine + Dexamethasone + Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 6723,
                    "therapyName": "Gemcitabine + Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 6725,
                    "therapyName": "Cisplatin + Cytarabine + Dexamethasone + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03424122",
            "title": "INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7351,
                    "therapyName": "Ibrutinib + Parsaclisib",
                    "synonyms": null
                },
                {
                    "id": 7350,
                    "therapyName": "Bendamustine + Parsaclisib + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 7349,
                    "therapyName": "Parsaclisib + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03424603",
            "title": "Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7413,
                    "therapyName": "STRO-001",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03440567",
            "title": "Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6780,
                    "therapyName": "Avelumab + Carboplatin + Etoposide + Ifosfamide + Rituximab + Utomilumab",
                    "synonyms": null
                },
                {
                    "id": 6781,
                    "therapyName": "Avelumab + Ibrutinib + Rituximab + Utomilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03460977",
            "title": "PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6785,
                    "therapyName": "PF-06821497",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03467373",
            "title": "A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5647,
                    "therapyName": "Tocilizumab",
                    "synonyms": null
                },
                {
                    "id": 6257,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine",
                    "synonyms": "Obinutuzumab + CHOP"
                },
                {
                    "id": 2195,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Rituximab + CHOP|RCHOP"
                },
                {
                    "id": 5764,
                    "therapyName": "RO7082859",
                    "synonyms": null
                },
                {
                    "id": 7620,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + RO7082859 + Vincristine",
                    "synonyms": "Obinutuzumab + RO7082859 + CHOP"
                },
                {
                    "id": 7621,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + RO7082859 + Vincristine",
                    "synonyms": "Rituximab + RO7082859 + CHOP"
                }
            ]
        },
        {
            "nctId": "NCT03479268",
            "title": "Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7712,
                    "therapyName": "Ibrutinib + MLN4924",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03483103",
            "title": "Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5980,
                    "therapyName": "JCAR017",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03484819",
            "title": "Copanlisib and Nivolumab in Treating Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6899,
                    "therapyName": "Copanlisib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03488251",
            "title": "PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7992,
                    "therapyName": "Gemcitabine + MT-3724 + Oxaliplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03537482",
            "title": "APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8825,
                    "therapyName": "APG-2575",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03538028",
            "title": "A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6977,
                    "therapyName": "INCAGN02385",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03543813",
            "title": "PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8915,
                    "therapyName": "CX-2029",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03547115",
            "title": "A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 842,
                    "therapyName": "Voruciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03558750",
            "title": "Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 7053,
                    "therapyName": "Lenalidomide + Nivolumab + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03586024",
            "title": "Phase I/II Study of Pembrolizumab in Patients With Relapsed or Refractory Extranodal NK/T- Cell Lymphoma (ENKTL), Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas (EBV-DLBCL)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03589469",
            "title": "Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7372,
                    "therapyName": "Loncastuximab tesirine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03598608",
            "title": "Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4213,
                    "therapyName": "MK-4280 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03610724",
            "title": "Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients (BIANCA)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5981,
                    "therapyName": "Tisagenlecleucel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03630159",
            "title": "Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients (PORTIA)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7643,
                    "therapyName": "Pembrolizumab + Tisagenlecleucel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03645395",
            "title": "PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8222,
                    "therapyName": "Lenalidomide + MT-3724",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03671018",
            "title": "A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2195,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Rituximab + CHOP|RCHOP"
                },
                {
                    "id": 2488,
                    "therapyName": "Cyclophosphamide + Prednisone + Rituximab + Vincristine",
                    "synonyms": "R-CHOP"
                },
                {
                    "id": 7624,
                    "therapyName": "Bendamustine + Polatuzumab vedotin-piiq + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 5225,
                    "therapyName": "Bendamustine + Obinutuzumab",
                    "synonyms": null
                },
                {
                    "id": 7623,
                    "therapyName": "BTCT4465A + Polatuzumab vedotin-piiq",
                    "synonyms": null
                },
                {
                    "id": 6304,
                    "therapyName": "BTCT4465A",
                    "synonyms": null
                },
                {
                    "id": 1646,
                    "therapyName": "Obinutuzumab",
                    "synonyms": null
                },
                {
                    "id": 5647,
                    "therapyName": "Tocilizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03677141",
            "title": "A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5647,
                    "therapyName": "Tocilizumab",
                    "synonyms": null
                },
                {
                    "id": 7627,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 7626,
                    "therapyName": "BTCT4465A + Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone",
                    "synonyms": null
                },
                {
                    "id": 7625,
                    "therapyName": "BTCT4465A + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine",
                    "synonyms": "BTCT4465A + CHOP"
                }
            ]
        },
        {
            "nctId": "NCT03677154",
            "title": "A Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable to Tolerate Full-Dose Chemotherapy",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7645,
                    "therapyName": "BTCT4465A + Tocilizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03682796",
            "title": "Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8156,
                    "therapyName": "TRPH-222",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03685344",
            "title": "Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7646,
                    "therapyName": "Durvalumab + Loncastuximab tesirine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03696784",
            "title": "Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5992,
                    "therapyName": "Rimiducid",
                    "synonyms": null
                },
                {
                    "id": 7976,
                    "therapyName": "Bendamustine + Fludarabine + iC9/CAR.19/IL15-Transduced CB-NK",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03703167",
            "title": "Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1610,
                    "therapyName": "Ibrutinib + Lenalidomide + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03704714",
            "title": "Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7718,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Nivolumab + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Nivolumab + Rituximab + CHOP"
                }
            ]
        },
        {
            "nctId": "NCT03740529",
            "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9507,
                    "therapyName": "Cyclophosphamide + Doxorubicin + LOXO-305 + Prednisone + Rituximab + Vincristine",
                    "synonyms": "LOXO-305 + R-CHOP"
                },
                {
                    "id": 9506,
                    "therapyName": "LOXO-305 + Rituximab + Venetoclax",
                    "synonyms": null
                },
                {
                    "id": 9505,
                    "therapyName": "LOXO-305 + Venetoclax",
                    "synonyms": null
                },
                {
                    "id": 9504,
                    "therapyName": "LOXO-305",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03742258",
            "title": "Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7648,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + TAK-659 + Vincristine",
                    "synonyms": "Rituximab + TAK-659 + CHOP"
                },
                {
                    "id": 2195,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Rituximab + CHOP|RCHOP"
                }
            ]
        },
        {
            "nctId": "NCT03743246",
            "title": "A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9578,
                    "therapyName": "Cyclophosphamide + Fludarabine + JCAR017",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03758989",
            "title": "A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2195,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Rituximab + CHOP|RCHOP"
                }
            ]
        },
        {
            "nctId": "NCT03797261",
            "title": "A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 7706,
                    "therapyName": "AMG 176 + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03843294",
            "title": "Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9629,
                    "therapyName": "MultiTAA-specific T cells + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03876028",
            "title": "Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8082,
                    "therapyName": "Ibrutinib + Tisagenlecleucel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03884998",
            "title": "Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6899,
                    "therapyName": "Copanlisib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03886831",
            "title": "A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9735,
                    "therapyName": "PRT543",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03892044",
            "title": "Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8116,
                    "therapyName": "Duvelisib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03894618",
            "title": "SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8683,
                    "therapyName": "SL-279252",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03920631",
            "title": "Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03934814",
            "title": "Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8233,
                    "therapyName": "TJ011133",
                    "synonyms": null
                },
                {
                    "id": 8235,
                    "therapyName": "Pembrolizumab + TJ011133",
                    "synonyms": null
                },
                {
                    "id": 8234,
                    "therapyName": "Rituximab + TJ011133",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03939182",
            "title": "Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8303,
                    "therapyName": "Abexinostat + Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03955783",
            "title": "Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8390,
                    "therapyName": "Selinexor + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03960840",
            "title": "CD19-specific CAR-T Cells in CLL/SLL and DLBCL",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8644,
                    "therapyName": "Ibrutinib + YTB323",
                    "synonyms": null
                },
                {
                    "id": 8643,
                    "therapyName": "YTB323",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03984448",
            "title": "Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5294,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Venetoclax + Vincristine",
                    "synonyms": "Venetoclax + DA-EPOCH-R"
                },
                {
                    "id": 8510,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine",
                    "synonyms": "DA-EPOCH-R"
                },
                {
                    "id": 2195,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Rituximab + CHOP|RCHOP"
                },
                {
                    "id": 8851,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Venetoclax + Vincristine",
                    "synonyms": "R-CHOP + Venetoclax"
                }
            ]
        },
        {
            "nctId": "NCT03990961",
            "title": "Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03995147",
            "title": "Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8497,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Pembrolizumab + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Pembrolizumab + R-CHOP"
                }
            ]
        },
        {
            "nctId": "NCT03997968",
            "title": "A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8486,
                    "therapyName": "CYT01B",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04002401",
            "title": "Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Either Rituximab or Lenalidomide in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8865,
                    "therapyName": "Cyclophosphamide + Fludarabine + KTE-C19 + Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 8864,
                    "therapyName": "Cyclophosphamide + Fludarabine + KTE-C19 + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04002947",
            "title": "Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8511,
                    "therapyName": "Acalabrutinib + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Acalabrutinib + DA-EPOCH-R"
                },
                {
                    "id": 8510,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine",
                    "synonyms": "DA-EPOCH-R"
                },
                {
                    "id": 8512,
                    "therapyName": "Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Acalabrutinib + RCHOP"
                },
                {
                    "id": 2195,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Rituximab + CHOP|RCHOP"
                }
            ]
        },
        {
            "nctId": "NCT04007029",
            "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5647,
                    "therapyName": "Tocilizumab",
                    "synonyms": null
                },
                {
                    "id": 8530,
                    "therapyName": "Anti-CD19/CD20 CAR T cells + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04074330",
            "title": "A Study of TAK-981 in Combination With Rituximab in Participants With Relapsed/Refractory (r/r) CD20-positive (CD20+) Non-Hodgkin Lymphoma (NHL)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9146,
                    "therapyName": "Rituximab + TAK-981",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04082936",
            "title": "A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9443,
                    "therapyName": "IGM-2323",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04134936",
            "title": "Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9188,
                    "therapyName": "Cyclophosphamide + Doxorubicin + MOR208 + Prednisone + Rituximab + Vincristine",
                    "synonyms": "MOR208 + R-CHOP"
                },
                {
                    "id": 9189,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Lenalidomide + MOR208 + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Lenalidomide + MOR208 + R-CHOP"
                }
            ]
        },
        {
            "nctId": "NCT04139304",
            "title": "A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9656,
                    "therapyName": "Cyclophosphamide + Daratumumab + Doxorubicin + Etoposide + Prednisone + Vincristine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04160195",
            "title": "T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 8529,
                    "therapyName": "Anti-CD19/CD20 CAR T cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04182204",
            "title": "A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5090,
                    "therapyName": "Gemcitabine + Oxaliplatin + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 9128,
                    "therapyName": "Gemcitabine + Oxaliplatin + Polatuzumab vedotin-piiq + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04205409",
            "title": "Nivolumab for the Treatment of Relapsed or Refractory Hematologic Malignancies",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04205838",
            "title": "Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9784,
                    "therapyName": "Anakinra + Cyclophosphamide + Fludarabine + KTE-C19",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04231747",
            "title": "A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9650,
                    "therapyName": "CC-97540",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04231877",
            "title": "Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9654,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Polatuzumab vedotin-piiq + Prednisone + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04257578",
            "title": "Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9318,
                    "therapyName": "Acalabrutinib + KTE-C19",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04283097",
            "title": "Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9479,
                    "therapyName": "KPG-818",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04323956",
            "title": "Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9628,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Parsaclisib + Pegfilgrastim + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Parsaclisib + Pegfilgrastim + R-CHOP"
                }
            ]
        }
    ]
}